Status:
COMPLETED
Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Pseudoexfoliation Syndrome
Glaucoma
Eligibility:
All Genders
18-80 years
Brief Summary
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point ...
Detailed Description
Hypothesis: Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation in ...
Eligibility Criteria
Inclusion
- German native speakers
- Age between 18-80 years
- Pseudoexfoliation syndrome
- Pseudoexfoliation syndrome with open-angle glaucoma
- Primary open-angle glaucoma
Exclusion
- Any history of ocular or systemic diseases other than glaucoma or of drug or alcohol abuse.
- Any condition potentially interfering with the visual field results. Visual fields will be obtained from the chart.
- Any mentally impaired patient.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00327613
Start Date
June 1 2005
End Date
April 1 2008
Last Update
September 26 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Eye Clinic Basel
Basel, Canton of Basel-City, Switzerland, 4031